Boc-(D)-(NⁱBoc)-Trp-N(Me)-(D)-(NⁱBoc)-Trp-NH2 | 501122-27-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-(D)-(NⁱBoc)-Trp-N(Me)-(D)-(NⁱBoc)-Trp-NH2
• 英文别名: Boc-D-Trp(Boc)-D-N(Me)Trp(Boc)-NH2；tert-butyl 3-[(2R)-3-[[(2R)-1-amino-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]-1-oxopropan-2-yl]-methylamino]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxopropyl]indole-1-carboxylate
• CAS: 501122-27-6
• 化学式: C₃₈H₄₉N₅O₈
• 分子量: 703.836
• InChiKey: RBAYCMKURNHRRQ-POURPWNDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  51
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  164
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Boc-(D)-(NⁱBoc)-Trp-N(Me)-(D)-(NⁱBoc)-Trp-NH2 在 吡啶 、 茴香硫醚 、 苯甲醚 、 N,N-二异丙基乙胺 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 H-(D)-Trp-N(Me)-(D)-gTrp-C(O)CH3*TFA
  参考文献：
  名称：

  New Active Series of Growth Hormone Secretagogues

  摘要：

  New growth hormone secretagogue (GHS) analogues were synthesized and evaluated for growth hormone releasing activity. This series derived from EP-51389 is based on a gem-diamino structure. Compounds that exhibited higher in vivo GH-releasing potency than hexarelin in rat (subcutaneous administration) were then tested per os in beagle dogs and for their binding affinity to human pituitary GHS receptors and to hGHS-R 1a. Compound 7 (JMV 1843, H-Aib-(D)-Trp-(D)-gTrp-formyl) showed high potency in these tests and was selected for clinical studies.(1)

  DOI：

  10.1021/jm020985q
• 作为产物：
  描述：

  D-tryptophan amide 在 N-甲基吗啉 、 4-二甲氨基吡啶 、 potassium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 苯硫酚 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 6.25h， 生成 Boc-(D)-(NⁱBoc)-Trp-N(Me)-(D)-(NⁱBoc)-Trp-NH2
  参考文献：
  名称：

  New Active Series of Growth Hormone Secretagogues

  摘要：

  New growth hormone secretagogue (GHS) analogues were synthesized and evaluated for growth hormone releasing activity. This series derived from EP-51389 is based on a gem-diamino structure. Compounds that exhibited higher in vivo GH-releasing potency than hexarelin in rat (subcutaneous administration) were then tested per os in beagle dogs and for their binding affinity to human pituitary GHS receptors and to hGHS-R 1a. Compound 7 (JMV 1843, H-Aib-(D)-Trp-(D)-gTrp-formyl) showed high potency in these tests and was selected for clinical studies.(1)

  DOI：

  10.1021/jm020985q